ITD seminar | Acinetobacter and AMR

Summary Dr Wareham is a clinical microbiologist with particular interests in infection control and antibiotic stewardship in intensive care unit. They apply a range of methodologies, including genomics, molecular biology, in vitro and in vivo models, and analysis of epidemiological and clinical data in areas such as outbreak characterisation, surveillance, diagnostic evaluation and assessment of […]

APPG | How to incentivise the development of antibiotics: lessons from malaria drug research partnerships

All-Party Parliamentary Group on Malaria & Neglected Tropical Diseases This is a joint event between the APPG on Antibiotics and the APPG on Malaria & NTDs Chaired by Julian Sturdy MP and Jeremy Lefroy MP   Guest speakers    Dr David Reddy, Chief Executive Officer of Medicines for Malaria Venture: Incentivising drug discovery: what have […]

PHP PhD Upgrading | Exploring the effectiveness, acceptability, and equity of access of rapid diagnostic tests for antimicrobial resistance in hospitals in the United Kingdom

Speaker: Rebecca Glover Supervisors: Mark Petticrew, Sharon Peacock Dept: PHES Date: Monday 26th February Time: 2.30pm Venue: G1, Jenny Roberts Room, Tavistock Place   ***ALL WELCOME***

Seminar | Which government policies actually reduce human antimicrobial use?

Summary As governments face domestic and international pressure to tackle antimicrobial resistance (AMR), policy strategies such as regulating antimicrobial sales and restricting use of last-resort drugs have become key strategies to reduce antimicrobial use. To inform future action, governments should have access to synthesized data on the effectiveness of large-scale AMR interventions. We have conducted […]

Rapid Support Team Meeting | Detecting and assessing public health risks around the clock: how the WHO Health Emergencies Programme is keeping the world safe

Details Speaker: Dr. Oliver Morgan, Director Health Emergency Information & Risk Assessment, Health Emergencies Programme, World Health Organization Date: 12 February 2018 Time: 12:30 – 14:00 Venue: LG81, Keppel Street

Seminar | Candida auris – the national and international update on a global emerging pathogen

Details Speaker: Colin Brown Date: 6 February Venue: LG81, Keppel Street Time: 12:45 – 14:00  

Seminar | ‘Pull’ incentives: How should we value and contract for new antibiotics?

Summary The importance of “pull” incentives to ensure that new antibiotics are available to help fight anti-microbial resistance (AMR): how should we value and contract for new antibiotics? Antibiotic resistance is increasingly rapidly and new antibiotics are urgently needed. Health Technology Assessment (HTA) and payer bodies need to be ready to respond appropriately to new […]

Seminar | Drug-resistant bacterial infections in Southeast Asia: problems and possible solutions

Co-hosted between the AMR Centre and CMMID     Details Speaker: Ben Cooper, Mahidol Oxford Research Unit Date: 23 January 2018 Time: 12:45 – 14:00 Venue: Jerry Morris B, Tavistock Place Watch live or later Use this link to watch the seminar live, or watch afterwards. Ben Cooper Ben has been working as part of the mathematical and economic […]

Seminar | AMR-Scapes: Science Communication and Public Engagement

Summary Professor Andrea Whittaker will be speaking about the public engagement research project AMR-Scapes. AMR-Scapes is  funded by an Australian Research Council Discovery Project grant to research public engagements with advice regarding the rational and reduced use of antibiotics. Some of the themes that AMR-Scapes tackles include examining AMR news and health media messages, including scientific assumptions, […]

CMMID Seminar | Modelling the impact of new diagnostic tests on drug resistant gonorrhoea epidemiology

Summary Katy Turner will present results from a novel individual based network simulation model of gonorrhoea transmission in men who have sex with men. The model incorporates multiple strains, including drug resistant strains and flexible options to determine management of individual patients, based on individual diagnosis (e.g. new point of care tests), extended use existing […]